FDA Considers Mobi-C “Approvable”

In short

Spine company LDR, tells us it has received an “Approvable Letter” from the U.S. FDA for its Mobi-C® Cervical Disc. Mobi-C is a metal and polyethylene mobile bearing prosthesis specifically designed as a low-profile cervical intervertebral disc replacement for both one and two level applications.


In case you’ve not seen the expression in regulatory world before, “approvable” means pretty much what it says, namely that “we would be able to approve it, subject to you guys providing the evidence we need to support the approval”. Companies will seek an approvable notice if they want reassurance that they’re on the right track, because otherwise zillions can be spend chasing wild geese.

In this case, the FDA has determined that Mobi-C is approvable for two-level indications, subject to the satisfaction of all applicable requirements of the Quality System Regulations (21 CFR Part 820), as well as finalisation of the labeling and post-approval study. FDA will therefore issue an approval order, allowing commercial sale and distribution, after said requirements have been reviewed and determined to be acceptable.

Physician comments

“The Mobi-C two-level study data, as presented at the North American Spine Society (NASS) 2012 Annual Meeting, demonstrate the potential to treat two-level cervical disease using the Mobi-C Cervical Disc as an alternative to ACDF,” said Dr. Reginald Davis, Chief of Neurosurgery and Director of Neurosciences at the Greater Baltimore Medical Center. “The anticipated full approval of Mobi-C will give surgeons a valuable treatment option for patients with two-level disease, where there is no approved motion preserving option.”

Company comments

“We are pleased that the FDA, after an intensive review of our submission for Mobi-C, has determined it to be approvable based on the strength of the data provided in the premarket approval application (PMA). We are confident that we can efficiently complete the remaining requirements inherent in the full approval process and we anticipate commercial U.S. availability of Mobi-C in 2013,” said Christophe Lavigne, President and CEO of LDR. “Given the high incidence of two-level cervical disease, we are proud that Mobi-C may become the first cervical disc available to treat patients on-label that suffer from two-level pathology. I would like to thank and attribute this success to everyone involved in this study, especially the clinicians, study coordinators, the FDA, LDR employees, our partners and suppliers, and most importantly the patients who consented to participate in the first prospective study performed comparing Mobi-C to ACDF.”

Regulatory status

For now the Mobi-C® device is for investigational use only and is not available for use in the United States.